OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
about
Cancer immunotherapy: the beginning of the end of cancer?Tremelimumab: research and clinical developmentInfluence of immunoglobulin isotype on therapeutic antibody functionPrinciples of antibody-mediated TNF receptor activationStrategies for combining immunotherapy with radiation for anticancer therapyImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaPotent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsFc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target AntigenEnhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) bindingTumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor TherapyCombination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.Therapeutic use of anti-CTLA-4 antibodies.OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.FcγR requirements leading to successful immunotherapy.Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.Therapeutic targeting of CD70 and CD27.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Reversing T-cell Dysfunction and Exhaustion in Cancer.Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM WorkshopRoles of regulatory T cells in cancer immunity.Cutting edge: epigenetic regulation of Foxp3 defines a stable population of CD4+ regulatory T cells in tumors from mice and humans.Targeting PD-1/PD-L1 in lung cancer: current perspectives.Ontogeny of Tumor-associated CD4+CD25+Foxp3+ T-regulatory Cells.Signaling by Antibodies: Recent Progress.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancerConcurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.Roles for Innate Immunity in Combination Immunotherapies.Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
P2860
Q26752277-C63F68EB-FEE0-47A6-A2B5-9E6B3916D7EFQ26752822-E0614DCD-D1B4-4A7E-A0BD-CD21C1130107Q26772080-ABB59281-0CA5-4936-AC33-FDB9DF48859FQ26796270-B375CF9A-F701-4624-8B38-5210758B1A60Q26796675-00CE85D9-0D8B-43CA-B304-5F2F4D85E96FQ28069864-561CE4B8-4CD4-4382-A309-D22C7DECA42AQ33705698-DCCEE5B0-A319-4B5F-8569-A6FF81657AF0Q33707098-1000DAC0-337E-4014-9718-6F38BF6331AEQ34978570-4CF33BEC-74A1-474B-941E-389530B85115Q36024656-171366A9-DF0A-4F5D-A3ED-3F60EE7FD14FQ36056627-CD621817-C7B9-44AD-9D05-C0E3DBCA831EQ36216363-261E1F0D-7AB2-417F-914D-0AF73D97038BQ36349514-09685AB3-0843-48CE-BE37-2082DEDE8B9BQ36498243-D394F68C-8A9B-44B4-9EFF-E1D5FE33A9C9Q36907372-63A37995-A9AF-4504-916D-84A4A4F53D84Q37114367-E2D3E8B1-1181-4E95-AD74-4CC2EE5EBBE4Q37155745-D6180A26-022C-4B05-8CB0-0AA8FB32F543Q37180457-30BA2AF4-D610-4B91-8485-DAE62FDA1F7CQ38231154-340CCD2F-BE60-4849-95C3-F5543D811F52Q38374889-FD8C2067-5F56-42F5-A19D-6FABFE0730A0Q38413904-23C927AF-8F3B-4908-83CD-B7CDF304AACAQ38615360-2AD5713E-673E-41F5-BC35-3D2E98176596Q38746023-F62EE5B8-C204-49EC-B718-A9AF689C11DFQ38749841-6B646AF5-0CC0-4E10-9832-488E21F102FEQ38770814-FD329D1D-1B22-4F76-8F5B-5E03BA0E3CEEQ38779877-8DDF2154-B6C4-445A-B404-C358CF4317B3Q38782706-B09509FC-C727-4E21-982A-E598114B9793Q38809776-92DA513B-B61B-4B99-B031-B182B4001F52Q38821875-E290601F-603E-42B5-BD0C-1E2D9C5AD2BBQ38830072-64C1F018-5FA3-465C-BD02-AB4CD0A0F484Q38924558-88CC8A91-4B72-4910-A10E-DA1048D5ED4DQ38956294-4C93D186-B62A-40AA-A3FF-38C11CEF4542Q38985262-7B487355-7D4D-4D8C-9661-E81F6C2A3864Q39264890-0595CDE9-4E22-4E58-A6A1-B0080BE1E2FFQ39313794-26DF6ADA-F522-4E5E-963D-2456B4C58DB6Q40560816-63C18CA1-3593-4DF2-989F-A195C4595927Q41016369-A9AD4871-B570-49D7-9DA3-DD48F817E7B6Q41101471-3350FFB8-3F41-4F45-B588-7FB50FB297BBQ41996352-DD725B20-8AC0-41AA-8F88-B1462DFA4A36Q42280832-CCAB1794-FC3B-498B-89E6-E33CE45A1AB3
P2860
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@en
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@nl
type
label
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@en
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@nl
prefLabel
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@en
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@nl
P2093
P2860
P356
P1476
OX40 engagement depletes intra ...... leading to antitumor efficacy.
@en
P2093
Glenn Dranoff
Jennifer L Brogdon
Jimin Zhang
Nicholas S Wilson
Rose Jolicoeur
Yannick Bulliard
P2860
P304
P356
10.1038/ICB.2014.26
P577
2014-04-15T00:00:00Z